Newswise — Burnham Institute for Medical Research at Lake Nona (Burnham) today announced that Stephen Gardell, Ph.D. has joined the Institute as Director of Translational Research Resources and Adjunct Associate Professor. Dr. Gardell's appointment is an indication of Burnham's intent to conduct basic medical research that can be quickly transferred from the laboratory to the clinic. Translational research, typically the domain of pharmaceutical laboratories, is moving downstream into not-for-profit research institutes to accelerate drug discovery and the development of diagnostic markers.
"Dr. Gardell brings a unique combination of experience to the interdisciplinary team being created at Burnham. His scientific focus aligns perfectly with our programs focused on cardiovascular and metabolic diseases. His pharmaceutical experience in drug discovery will help our mission to move discovery science to the clinic along at a faster pace," said Dr. Daniel Kelly, Scientific Director at Burnham Lake Nona.
Dr. Gardell has extensive experience in research technology and drug development. He held senior positions at several large pharmaceutical companies, including Wyeth Laboratories where he was Assistant Vice President of Cardiovascular and Metabolic Disease. Previously, he directed obesity research at Bayer Research Center and biological chemistry at Merck Research Laboratories. Dr. Gardell received his undergraduate degree from Boston College and completed his Ph.D. studies at Cornell University in New York.
Dr. Gardell's pharmaceutical experience, including the successful identification of several drug candidates for clinical trials, will benefit Burnham investigators, as he advises the scientists on strategies to translate laboratory discoveries into clinical applications. Dr. Gardell will also oversee development and operation of the cardiometabolic and metabolomics technology cores and conduct independent and collaborative research.
About Burnham Institute for Medical ResearchBurnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest growing research institutes in the country. The Institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit, public benefit corporation. For more information, please visit www.burnham.org.
RSS